Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 5/20 | 0.47 |
| ▸ | WNT3A | P56704 | 5/20 | 0.47 |
| ▸ | MAOB | P27338 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
| ▸ | CLK2 | P49760 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6389862 | 0.91 | MAOB (0.47) | ROCK2ROCK1MAPK14MAOBNPC1 | |
| SCHEMBL6488542 | 0.81 | SMYD3 (0.55) | CTNNB1WNT3AMAOBNPC1RAB9A | |
| SCHEMBL6101484 | 0.81 | SSTR3 (0.47) | — | |
| SCHEMBL29455221 | 0.80 | EPHX2 (0.38) | ROCK2ROCK1 | |
| SCHEMBL6480026 | 0.78 | CHRNA7 (0.58) | MAPK14 | |
| SCHEMBL6099763 | 0.78 | DEGS1 (0.39) | NPC1RAB9ADYRK1A | |
| SCHEMBL14129897 | 0.78 | ROCK2 (0.50) | ROCK2ROCK1MAPK14MAOBNPC1 | |
| SCHEMBL6098549 | 0.77 | HTR3A (0.60) | NPC1RAB9A | |
| SCHEMBL18034970 | 0.77 | NPC1 (0.61) | ROCK2ROCK1MAPK14CTNNB1WNT3A | |
| SCHEMBL6099482 | 0.77 | F10 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176702-A1 | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-09-18 | — | — | US | claimed |
| US-6849620-B2 | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease | PFIZER INC (US) | 2005-02-01 | — | — | US | disclosed |
| US-20030176702-A1 | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176702-A1 | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease | CYP1B1, ABCB1, NAT1 | ROCK2 4353/4885ROCK1 4295/4885MAPK14 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.